Prospects of siRNA applications in regenerative medicine

Fatemeh Mottaghitalab, Ali Rastegari, Mehdi Farokhi, Rassoul Dinarvand, Hossein Hosseinkhani, Keng Liang Ou, Daniel W. Pack, Chuanbin Mao, Meshkat Dinarvand, Yousef Fatahi, Fatemeh Atyabi

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Small interfering RNA (siRNA) has established its reputation in the field of tissue engineering owing to its ability to silence the proteins that inhibit tissue regeneration. siRNA is capable of regulating cellular behavior during tissue regeneration processes. The concept of using siRNA technology in regenerative medicine derived from its ability to inhibit the expression of target genes involved in defective tissues and the possibility to induce the expression of tissue-inductive factors that improve the tissue regeneration process. To date, siRNA has been used as a suppressive biomolecule in different tissues, such as nervous tissue, bone, cartilage, heart, kidney, and liver. Moreover, various delivery systems have been applied in order to deliver siRNA to the target tissues. This review will provide an in-depth discussion on the development of siRNA and their delivery systems and mechanisms of action in different tissues.

Original languageEnglish
Pages (from-to)312-329
Number of pages18
JournalInternational Journal of Pharmaceutics
Volume524
Issue number1-2
DOIs
Publication statusPublished - May 30 2017

Keywords

  • Delivery systems
  • Gene expression
  • siRNA
  • Tissue engineering

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Prospects of siRNA applications in regenerative medicine'. Together they form a unique fingerprint.

  • Cite this

    Mottaghitalab, F., Rastegari, A., Farokhi, M., Dinarvand, R., Hosseinkhani, H., Ou, K. L., Pack, D. W., Mao, C., Dinarvand, M., Fatahi, Y., & Atyabi, F. (2017). Prospects of siRNA applications in regenerative medicine. International Journal of Pharmaceutics, 524(1-2), 312-329. https://doi.org/10.1016/j.ijpharm.2017.03.092